View examples of how we address the unique need of every research question to deliver innovative, multidimensional solutions to convey the value of healthcare innovations. Download our posters from recent conferences.

ISPOR 2020 Posters Link
Humanistic Burden Associated with Depression and Anxiety Among Adults with Non-Communicable Chronic Diseases (NCCDs) in the United States Download
Budget Impact Analysis of Introduction of Rituximab Biosimilar in the United States from a Payer Perspective Download
Comparison of Treatment Adherence And Persistence with Edoxaban Versus Apixaban, Dabigatran, Rivaroxaban, and Vitamin K Antagonist in Non-Valvular Atrial Fibrillation Patients in Germany: A Propensity Matched Cohort Study Download
Budget Impact Analysis of Introduction of Bevacizumab Biosimilar in the United States from a Payer Perspective Download
Budget Impact Analysis of Introduction of IV Trastuzumab Biosimilar (Trastuzumab-qyyp) from Buyer and Payer Perspectives in France Download
Real-World Economic and Clinical Outcomes Associated with Current Hemostatic Matrix Use in Spinal Surgery Download
Real-World Economic and Clinical Outcomes Associated with Current Hemostatic Matrix Use in Cardiovascular Surgery Download
ISPOR Europe Symposium Link
SURVIVAL MODELLING: TRENDS AND INNOVATIONS Download
ISPOR HEOR Theater Link
COMMUNICATING VALUE TO DECISION-MAKERS: WHAT’S YOUR PROGNOSIS? Download
ISPOR Europe 2019 Posters Link
COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY Download
COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB + IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAIN Download
COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND Download
UPDATED NETWORK META-ANALYSIS OF TREATMENTS IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA Download
STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA Download
COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE Download
COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE Download
USING MACHINE LEARNING FOR EFFICIENCY IMPROVEMENTS IN SYSTEMATIC LITERATURE REVIEWS OF CLINICAL EFFICACY AND SAFETY Download
BAYESIAN MODEL AVERAGING FOR EXTRAPOLATING SURVIVAL: A PAN-TUMOR PERSPECTIVE ON NIVOLUMAB AND IPILIMUMAB Download
MODELING THE SURVIVAL BENEFIT OF IMMUNO-ONCOLOGIC THERAPY: A REVIEW OF METHODS USED IN NICE SINGLE TECHNOLOGY APPRAISALS Download
COMPARISON OF TIME TO REIMBURSEMENT RECOMMENDATIONS OF (ORPHAN-) ONCOLOGY DRUGS IN EUROPE Download
MAXIMUM LIKELIHOOD ESTIMATION TO QUANTIFY THE IMPACT OF TREATMENT RESPONSE ON SURVIVAL OUTCOMES Download
BALANCING GLOBAL HTA REQUIREMENTS FOR LITERATURE REVIEWS ACROSS EUROPE, NORTH AMERICA, AND ASIA Download
IMPROVING THE ACCURACY AND REDUCING UNCERTAINTY OF PROBABILISTIC PARTITIONED SURVIVAL ANALYSES, BY CONSIDERING THE RELATIONSHIP BETWEEN PFS AND OS Download
AMCP Nexus 2019 Link
CHARACTERISTICS, SYSTEMIC TREATMENTS AND OUTCOMES IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A SYSTEMATIC LITERATURE REVIEW Download